Search clinical trials for: Nanoparticle Albumin Bound Paclitaxel

Total 1129 results

Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine
Zhejiang Cancer Hospital

Unknown

Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer

Breast Cancer
Celgene Corporation

Completed

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Harold J. Burstein, MD, PhD
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Celgene...

Completed

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

Breast Cancer

United States
Guo Xufeng

Recruiting

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Adjuvant Therapy | Neoadjuvant Chemoimmunotherapy

China
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene

Active, not recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Resectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

United States
Huazhong University of Science and Technology
Chongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaborators

Recruiting

Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Cervical Cancer | Uterine Cervical Cancer | Uterine Cervical Neoplasm

China
Orinove, Inc.

Active, not recruiting

ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Metastatic Breast Cancer | Advanced Solid Tumor

United States
Celgene

Completed

Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

Melanoma | Metastases

United States
Celgene Corporation

Completed

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

Breast Neoplasms | Metastases, Neoplasm

United States
Celgene Corporation

Completed

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Neoplasms | Metastases, Neoplasm

United States
Taiho Pharmaceutical Co., Ltd.

Completed

Phase II Study of ABI-007 for Gastric Cancer

Gastric Cancer

Japan
Masonic Cancer Center, University of Minnesota

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Lung Cancer
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Georgetown University

Terminated

Study of Gemcitabine and Abraxane for Pancreas Cancer

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)

Malignant Solid Neoplasm

United States
Fujian Medical University Union Hospital

Not yet recruiting

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Chemotherapy | Radiation Therapy

China
First People's Hospital of Foshan

Not yet recruiting

Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms
Memorial Sloan Kettering Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

HEAD & NECK Cancer

United States
Processa Pharmaceuticals

Completed

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
West China Hospital

Recruiting

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

Breast Cancer

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Washington University School of Medicine
Celgene

Completed

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

Head and Neck Neoplasms

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Actuate Therapeutics Inc.

Active, not recruiting

9-ING-41 in Patients With Advanced Cancers

Sarcoma | Cancer | Breast Neoplasms | Neoplasm Metastasis | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Bone Cancer | Malignant Glioma | Bone Metastases | Pancreas Cancer | Renal Cancer | Refractory Non-Hodgkin Lymphoma | Bone Neoplasm | Neoplasm, Breast | Refractory Cancer | Refractory Neoplasm | Resistant... and other conditions

United States, Belgium, Canada, Spain, France, Netherlands, Portugal
University of Utah
Celgene Corporation

Terminated

Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer (NAC)

Stages II-III Breast Cancer

United States
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer

Advanced Breast Cancer
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Withdrawn

Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

Ovarian Cancer | Endometrial Cancer | Recurrent Endometrial Cancer | Recurrent Ovarian Cancer
Washington University School of Medicine

Terminated

Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Jilin University

Not yet recruiting

Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer

Breast Cancer Stage

China
M.D. Anderson Cancer Center
Celgene

Completed

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Colorectal Cancer | Cancer of Gastrointestinal Tract

United States
Celgene

Completed

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

Pancreatic Cancer

United States, Canada, Spain, Australia, France, Germany, Austria, Italy, Ukraine
University Health Network, Toronto
Celgene Corporation

Completed

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer

Head and Neck Cancer

Canada
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer (OPTIMA)

Human Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx | Stage IVB Squamous Cell Carcinoma of the Oropharynx

United States
Beijing Tongren Hospital

Not yet recruiting

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine,...

Recruiting

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Ovarian Cancer | Neoadjuvant Chemotherapy | Anti-PD-1 | Neoadjuvant Immunotherapy

China
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Varian Medical Systems

Suspended

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage III Lung Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States
Fujian Medical University Union Hospital

Not yet recruiting

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

Immunotherapy;Envafolimab; Esophageal Cancer
Celgene

Terminated

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Tianjin Medical University

Unknown

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer

Breast Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma

United States
Genta Incorporated

Unknown

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Melanoma

United States
Yuhong Li

Completed

S-1 in Combination With Abraxane in Treating Cholangiocarcinoma

Cholangiocarcinoma

China
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Washington University School of Medicine
Celgene Corporation

Active, not recruiting

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (CACTUX)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Cancer of the Head and Neck

United States
Washington University School of Medicine
National Cancer Institute (NCI); BioMed Valley Discoveries, Inc

Terminated

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas

United States
Shengjing Hospital

Recruiting

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Breast Cancer

China

Search clinical trials for: Nanoparticle Albumin Bound Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations